

## **MEDIA STATEMENT**

PHILOGEN SPA ANNOUNCES PARTICIPATION IN THE “ANTIBODY ENGINEERING & THERAPEUTICS MEETING”, 11 – 15 DECEMBER 2016, SAN DIEGO, CA

[Philogen S.p.A.](#) and its fully owned subsidiary [Philochem AG](#), announce their participation to the “[Antibody Engineering & Therapeutics meeting](#)” that will take place at the Manchester Grand Hyatt of San Diego from December 11 to December 15, 2016.

The congress will gather more than 120 speakers and more than 800 global antibody scientists. The main purpose of the congress is to accelerate the next generation of antibodies toward commercial success.

**Prof. Dr. Dario Neri**, Swiss Federal Institute of Technology Zurich, co-founder and Chairman of the scientific advisory board of Philogen, will give a talk with the title “[Antibody-cytokine Fusion Proteins for the Therapy of Cancer and of Chronic Inflammation](#)”. The presentation is scheduled for Wednesday, December 14<sup>th</sup> at 3:15 pm.

For additional news and press release topics, visit: <http://www.philogen.com/en/news/>

### **About the Philogen group**

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com)

---